Return to Listing

12 result(s) for Lymphoma

PI Name Protocol # Title
Stephen Spurgeon IRB00010383 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-Lag-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
Rachel Cook IRB00011076 A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of LOR-253 in Patients with Relapsed or Refractory Hematologic Malignancies
Bart Moulton IRB00011150 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Stephen Spurgeon IRB00011311 A Phase 1/2 Proof-of-concept study of the combination of ACP-196 and ACP-319 in subjects with B-cell malignancies
Stephen Spurgeon IRB00011800 Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Brandon Hayes-Lattin IRB00011894 Protocol CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Brandon Hayes-Lattin IRB00011960 Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
Alexey Danilov STUDY00015136 A Phase 1B Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination with Other Targeted Anti-cancer Therapies in Subjects with B-cell Malignancies
Emma Scott STUDY00015214 A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Stephen Spurgeon STUDY00015255 IIT: A Phase II study of Obinutuzumab (GA-101) in Combination with Ibrutinib (I) for the Treatment of Relapsed Mantle Cell Lymphoma (ML29535)
Craig Okada STUDY00015315 Phase 1/2 Study of Intratumoral G100 With or Without Pembrolizumab in Patients with Follicular Non-Hodgkin's Lymphoma
Kim-Hien Dao STUDY00015363 WEAR in Oregon: Defining risks of blood cancer development in a cohort of older women with clonal hematopoiesis and TET2 mutations. (Women Engaged in Advancing health Research in Oregon is a prospective epidemiology study)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080